This resolution expresses support for the designation of National Prostate Cancer Awareness Month.
[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 584 Introduced in House (IH)]
<DOC>
116th CONGRESS
1st Session
H. RES. 584
Expressing support for the designation of September 2019 as ``National
Prostate Cancer Awareness Month''.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 24, 2019
Mr. Payne (for himself, Mr. Mullin, and Mr. Meeks) submitted the
following resolution; which was referred to the Committee on Energy and
Commerce, and in addition to the Committee on Ways and Means, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
RESOLUTION
Expressing support for the designation of September 2019 as ``National
Prostate Cancer Awareness Month''.
Whereas an estimated 3,110,403 men in the United States live with prostate
cancer;
Whereas, according to the National Cancer Institute, the percentage of newly
diagnosed prostate cancer cases in men under 65 has significantly
increased and stands at 41.9 percent;
Whereas 1 in 9 men in the United States will be diagnosed with prostate cancer
in their lifetimes;
Whereas prostate cancer is the most commonly diagnosed nonskin cancer and the
second-leading cause of cancer-related deaths among men in the United
States;
Whereas the American Cancer Society estimates that in 2019, 174,650 men will be
diagnosed with, and more than 31,620 men will die of, prostate cancer;
Whereas the odds of developing prostate cancer rise rapidly after age 50;
Whereas African-American men suffer from a prostate cancer incidence rate that
is significantly higher than that of White men and have more than double
the prostate cancer mortality rate than that of White men;
Whereas some veterans are at an increased risk of prostate cancer due to
chemical or radiation exposure during military service;
Whereas a study conducted at the Portland VA Medical Center and Oregon Health
and Science University found that veterans exposed to Agent Orange were
at an increased risk for both developing prostate cancer and developing
more aggressive forms of the disease;
Whereas having a father or brother with prostate cancer more than doubles the
risk of a man developing prostate cancer, with a higher risk for men who
have a brother with the disease and the highest risk for men with
several affected relatives;
Whereas screening by a digital rectal examination and a prostate-specific
antigen blood test can detect the disease at the earlier, more treatable
stages, which could increase the chances of survival for more than 5
years to nearly 100 percent;
Whereas prostate cancer is almost always diagnosed with a needle biopsy where
the prostate is mapped and tissue cores removed from at least a dozen
sites;
Whereas even with state-of-the-art laboratory techniques and specimen tracking,
the peer-reviewed literature reports that as many as 2.5 percent of
prostate biopsy patients are affected by biopsy tissue switching or
contamination leading to misdiagnosis;
Whereas misdiagnosis can result in inappropriate over- or under-treatment of
men;
Whereas only 30 percent of men survive more than 5 years if diagnosed with
prostate cancer after the cancer has metastasized;
Whereas there are no noticeable symptoms of prostate cancer in the early stages,
making appropriate screening critical;
Whereas ongoing research promises further improvements in prostate cancer
prevention, early detection, and treatment; and
Whereas educating people in the United States, including health care providers,
about prostate cancer and early detection strategies is crucial to
saving the lives of men and preserving and protecting families: Now,
therefore, be it
Resolved, That the House of Representatives--
(1) expresses support for the designation of ``National
Prostate Cancer Awareness Month'';
(2) declares that steps should be taken--
(A) to raise awareness about the importance of
screening methods for, and treatment of, prostate
cancer;
(B) to encourage research--
(i) to improve screening and treatment for
prostate cancer;
(ii) to discover the causes of prostate
cancer; and
(iii) to develop a cure for prostate
cancer;
(C) support Medicare payment policies that will
improve diagnostic accuracy and eliminate prostate
cancer misdiagnosis due to biopsy contamination or
specimen switching; and
(D) to continue to consider ways for improving
access to, and eliminating racial disparities in, the
quality of health care services for detecting and
treating prostate cancer; and
(3) calls on the people of the United States, interest
groups, and affected persons--
(A) to promote awareness of prostate cancer;
(B) to take an active role in the fight to end the
devastating effects of prostate cancer on individuals,
families, and the economy; and
(C) to observe National Prostate Cancer Awareness
Month with appropriate ceremonies and activities.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line